Part 2 – Results of the EMERALD trial in a cohort of HR+ MBC patients without an identified ESR1 mutation
The first Huddle was so popular, GRASP had to host a second one! With a different group of advocates, Dr. Kaklamani, MD DSc will once again discuss the EMERALD trial which is the first to show that a new type of hormone therapy called an oral SERD (selective estrogen receptor degrader) improves outcomes in patients with hormone receptor positive (HR+) metastatic breast cancer (MBC). In this trial, she studied a group of women with no identified ESR1 mutation in their cancer based on prior CDK4/6 treatment duration. We will discuss the results of this study and review the poster, “Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer” that was presented at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO).
Virginia KaklamaniProfessor of Medicine, UT Health San Antonio, MD Anderson Cancer Center
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
Dr. Kaklamani is Professor of Medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center in San Antonio and is the Leader of the Breast Cancer Program at the Mays Cancer Center. Dr. Kaklamani completed her medical training with honors at the University of Athens and her residency in Internal Medicine at Newton-Wellesley Hospital in Boston, MA. She completed her fellowship in hematology/oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was Head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution. Dr. Kaklamani has also served as the Associate Director for Clinical Research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. Dr. Kaklamani has also identified several genetic mutations that link obesity and breast cancer.